151 related articles for article (PubMed ID: 25537338)
1. A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid.
Ogata K; Takamura N; Tokunaga J; Ikeda T; Setoguchi N; Tanda K; Yamasaki T; Nishio T; Kawai K
Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):179-86. PubMed ID: 25537338
[TBL] [Abstract][Full Text] [Related]
2. Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats.
Ogata K; Takamura N; Tokunaga J; Kawai K; Arimori K; Higuchi S
J Pharm Pharmacol; 2008 Jan; 60(1):15-20. PubMed ID: 18088500
[TBL] [Abstract][Full Text] [Related]
3. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
Nobilis M; Mikušek J; Szotáková B; Jirásko R; Holčapek M; Chamseddin C; Jira T; Kučera R; Kuneš J; Pour M
J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
[TBL] [Abstract][Full Text] [Related]
4. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
Soma LR; Uboh CE; Rudy JA; Smith MS
Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
[TBL] [Abstract][Full Text] [Related]
5. A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes.
Matsumoto K; Hasegawa T; Ohara K; Takei C; Kamei T; Koyanagi J; Takahashi T; Akimoto M
Xenobiotica; 2020 Jul; 50(7):783-792. PubMed ID: 31855101
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone.
Matsumoto K; Nemoto E; Hasegawa T; Akimoto M; Sugibayashi K
Biol Pharm Bull; 2011; 34(5):734-9. PubMed ID: 21532165
[TBL] [Abstract][Full Text] [Related]
7. Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid
Matsumoto K; Hasegawa T; Ohara K; Kamei T; Koyanagi J; Akimoto M
Xenobiotica; 2021 Feb; 51(2):155-166. PubMed ID: 33146575
[TBL] [Abstract][Full Text] [Related]
8. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.
Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Giersch KH; Münzel P
Drugs; 1990; 40 Suppl 5():57-61. PubMed ID: 2081495
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of an anti-inflammatory-histamine H2 antagonist drug complex on gastric erosions in the rat.
Imai T; Fukuhara A; Ueda I; Otagiri M
J Pharmacol Exp Ther; 1993 Apr; 265(1):328-33. PubMed ID: 8097246
[TBL] [Abstract][Full Text] [Related]
10. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
Dandona P; Jeremy JY
Drugs; 1990; 40 Suppl 5():16-24. PubMed ID: 2081487
[TBL] [Abstract][Full Text] [Related]
11. Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil.
He Y; Qin M; Li M; Zhi D; Tian B; Qin F
Chirality; 2023 Apr; 35(4):247-255. PubMed ID: 36759185
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of hydroxyimine as cytochrome P450-selective prodrug structure.
Kumpulainen H; Mähönen N; Laitinen ML; Jaurakkajärvi M; Raunio H; Juvonen RO; Vepsäläinen J; Järvinen T; Rautio J
J Med Chem; 2006 Feb; 49(3):1207-11. PubMed ID: 16451086
[TBL] [Abstract][Full Text] [Related]
13. Potential of Piperazinylalkylester Prodrugs of 6-Methoxy-2-Naphthylacetic Acid (6-MNA) for Percutaneous Drug Delivery.
Pawar V; Thosani R; Kanhed A; Giridhar R; Yadav MR
AAPS PharmSciTech; 2015 Jun; 16(3):518-27. PubMed ID: 25370023
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective disposition of flurbiprofen from a mutual prodrug with a histamine H2-antagonist to reduce gastrointestinal lesions in the rat.
Fukuhara A; Imai T; Otagiri M
Chirality; 1996; 8(7):494-502. PubMed ID: 8970747
[TBL] [Abstract][Full Text] [Related]
15. A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis.
Setoguchi N; Takamura N; Fujita K; Ogata K; Tokunaga J; Nishio T; Chosa E; Arimori K; Kawai K; Yamamoto R
Biopharm Drug Dispos; 2013 Mar; 34(2):125-36. PubMed ID: 23225308
[TBL] [Abstract][Full Text] [Related]
16. Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect.
Světlík S; Štícha M; Matoušková O; Nespěšná L; Sklenář Z; Bartůněk A; Perlík F; Slanař O
Am J Ther; 2016; 23(6):e1498-e1503. PubMed ID: 25393072
[TBL] [Abstract][Full Text] [Related]
17. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
[TBL] [Abstract][Full Text] [Related]
18. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?
Davies NM
Clin Pharmacokinet; 1997 Dec; 33(6):404-16. PubMed ID: 9435990
[TBL] [Abstract][Full Text] [Related]
20. Polymorphonuclear leukocytes activation: in vitro modulation by 6-methoxy-2-naphthylacetic acid, the major active metabolite of nabumetone.
Allegrezza-Giulietti A; Serretti R; Peroni M; Cervini C
Pharmacol Res; 1993 Sep; 28(2):163-73. PubMed ID: 8278307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
